Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Scentre Group releases 2025 Modern Slavery Statement

Scentre Group releases 2025 Modern Slavery Statement

ReutersReuters2026/08/04 00:03
  • Scentre Group filed a 2025 Modern Slavery Statement covering actions to identify, assess, and address forced-labor risks across operations and suppliers.
  • Risk focus remained labor-hire services, mainly cleaning, security, construction, and technology supply chains with overseas sourcing exposure.
  • Strengthened supplier onboarding, risk reviews, due diligence, sanctions screening, and ongoing engagement with higher-risk suppliers.
  • Ran seven unscheduled after-hours spot checks with cleaning and security workers; tracked supplier observations for emerging risk trends.
  • Recorded five supplier-worker grievances; two related to pay or entitlements, including one subcontractor matter still under investigation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scentre Group published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI Agents On XRP. Here’s What Is Happening

TimesTabloid2026/08/18 08:00

AstraZeneca (AZN.US) monoclonal antibody new drug approved for two indications in China

AstraZeneca (AZN.US) announced the official launch of Tezelyumab injection in China.

智通财经2026/08/18 07:56
AstraZeneca (AZN.US) monoclonal antibody new drug approved for two indications in China